BMEA241220C15000
- 0.30
- -0.16-34.78%
Biomea Fusion Newsroom
D. Boral Maintains Buy Rating, $128 Target on Biomea Fusion After Presentations
Express News | Biomea Fusion Says In Preclinical Experiments, Icovamenib Enhanced Beta Cell Function And Responsiveness Of Human Islets To GLP-1-Based Therapies
Express News | Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22Nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (Wcirdc)
Biomea Fusion Slides As Insider Purchases Lose Another US$26k
Biomea Fusion Price Target Maintained With a $128.00/Share by D. Boral Capital
Biomea Fusion Is Maintained at Buy by D. Boral Capital
J.P. Morgan Maintains Biomea Fusion(BMEA.US) With Hold Rating, Maintains Target Price $11
Promising Phase 1 Results for Biomea Fusion's BMF-500 Support Buy Rating
Barclays Maintains Biomea Fusion(BMEA.US) With Hold Rating, Raises Target Price to $11
Biomea Fusion (BMEA) Gets a Hold From Barclays
Biomea Fusion Reports Preliminary Data From Experimental Cancer Therapy Study; Shares Rise After Hours
Biomea Fusion Announces Preliminary COVALENT-103 Study Data
Biomea Fusion Announces Preliminary Data From Ongoing COVALENT-103 Study Of Investigational Covalent FLT3 Inhibitor BMF-500 In Relapsed Or Refractory Acute Leukemia
Express News | Biomea Fusion Inc - Bmf-500 Shows Favorable Safety Profile With No Dose-Limiting Toxicities
Express News | Biomea Fusion Announces Preliminary Data From Ongoing Covalent-103 Study of Investigational Covalent Flt3 Inhibitor Bmf-500 in Relapsed or Refractory Acute Leukemia
Scotiabank Sticks to Their Buy Rating for Biomea Fusion (BMEA)
H.C. Wainwright Maintains Biomea Fusion(BMEA.US) With Buy Rating, Maintains Target Price $40
Biomea Fusion Price Target Maintained With a $40.00/Share by HC Wainwright & Co.
Positive Buy Recommendation for Biomea Fusion Amid Promising Diabetes Treatment Developments in COVALENT-111 Phase 2 Trial
Express News | D. Boral Capital Maintains Buy on Biomea Fusion, Maintains $128 Price Target